Unicycive CEO to Present at Needham Conference

Live webcast starts at 3:45 p.m. ET on April 15, 2026

Apr. 9, 2026 at 11:05am

Got story updates? Submit your updates here. ›

A minimalist neon outline of a human kidney, with glowing blue and violet lines pulsing through the organ against a dark background, conceptually representing Unicycive's work in developing new therapies for kidney disease.Unicycive's pipeline of kidney disease treatments aims to address critical unmet needs for patients.Los Altos Today

Unicycive Therapeutics, a clinical-stage biotechnology company developing therapies for patients with kidney disease, announced that CEO Shalabh Gupta, M.D. will present at the 25th Annual Needham Virtual Healthcare Conference on April 15, 2026 at 3:45 p.m. ET. The live webcast will be available on the company's website.

Why it matters

Unicycive's lead investigational treatment, oxylanthanum carbonate, is currently under review by the FDA for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis. The company's second investigational treatment, UNI-494, is intended for the treatment of acute kidney injury and has received orphan drug designation from the FDA.

The details

The live webcast of Dr. Gupta's presentation at the Needham conference will be available on Unicycive's website under the Investors section. Investors will have the opportunity to hear directly from the CEO about the company's pipeline and ongoing development efforts.

  • The presentation will take place on Wednesday, April 15, 2026 at 3:45 p.m. ET.
  • The webcast will remain archived online after the live event.

The players

Unicycive Therapeutics, Inc.

A clinical-stage biotechnology company developing therapies for patients with kidney disease.

Shalabh Gupta, M.D.

Chief Executive Officer of Unicycive Therapeutics.

Got photos? Submit your photos here. ›

The takeaway

Unicycive's presentation at the Needham conference provides an opportunity for investors to learn more about the company's pipeline and ongoing development efforts, particularly around its lead investigational treatment for chronic kidney disease patients.